Kearny Financial’s Director, Curtland E. Fields, purchased 14,700 shares of KRNY for $138,274 at $9.41 each on Monday. As of Tuesday, KRNY was trading at a high of $9.76, representing an increase of about 3.8% from the purchase price. In the past year, Fields has invested a total of $181,191 in KRNY, averaging $8.51 per share.
On Thursday, Scribe Therapeutics’ Chief Financial Officer, David Parrot, bought 2,666 shares at $15.00 each for a total of $39,990, marking his first insider buy in the past year. By Tuesday, Parrot’s investment had increased by approximately 25.9%, with shares reaching a high of $18.89.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
